Q1 2026 saw 20% revenue growth, 70% higher net income, and strong digital expansion, with market share up 150 bps and stable margins. Efficiency gains, inventory reduction, and successful 4Bio divestment support a positive outlook despite regulatory and competitive pressures.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.